ABSTRACT
It is unclear whether higher CD34 + cell doses infused for ASCT have any influence on survival or relapse in patients with lymphoma. We analyzed the correlation of infused CD34 + cell dose with relapse, survival, and hematopoietic recovery in 146 consecutive patients undergoing ASCT for lymphoma. Higher doses (>5 × 106/kg) were significantly correlated with earlier hematopoietic recovery, fewer infectious episodes, lower transfusion needs. No differences were observed in lymphoma outcomes (4-year relapse incidence of 38% [95%CI: 29%-48%] in the lower dose group versus 51% [95%CI: 30%-69%] in the higher dose group, 10-year OS probabilities of 58% [95%CI: 48%-68%] versus 75% [95%CI: 59%-91%], 10-year DFS probabilities of 47% [95%CI: 37%-57%] versus 42% [95%CI: 23%-61%], p = NS for all outcomes). In this series, a higher infused CD34 + cell dose did not correlate with survival or relapse but correlated with earlier hematopoietic recovery and lower resource consumption.
Subject(s)
Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells , Lymphoma/pathology , Lymphoma/therapy , Adolescent , Adult , Aged , Antigens, CD34/metabolism , Child , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cells/metabolism , Humans , Lymphoma/mortality , Male , Middle Aged , Neoplasm Staging , Recurrence , Retreatment , Risk , Transplantation, Autologous , Treatment Outcome , Young AdultSubject(s)
Antiviral Agents/adverse effects , Interferon-beta/adverse effects , Purpura, Thrombotic Thrombocytopenic/chemically induced , Adult , Antiviral Agents/administration & dosage , Hepatitis C/diagnosis , Hepatitis C/drug therapy , Humans , Interferon-alpha/administration & dosage , Interferon-alpha/adverse effects , Interferon-beta/administration & dosage , Male , Middle Aged , Multiple Sclerosis/diagnosis , Multiple Sclerosis/drug therapy , Purpura, Thrombotic Thrombocytopenic/diagnosis , Ribavirin/administration & dosage , Ribavirin/therapeutic use , Time FactorsABSTRACT
No disponible
